purin-hydrazone支架作为潜在的EGFR/HER2双抑制剂
Fatemah S Albalawi1,2, Mashooq A Bhat2, Ahmed H Bakheit2
1School of Pharmacy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Pharmaceuticals (Basel, Switzerland)
|July 30, 2025
概括
新的含精氨酸的氨酸通过准表皮生长因子受体 (EGFR) 和人体表皮生长因子受体2 (HER2) 来表现出强大的抗癌活性. 化合物19a,16b和22b表现出显著的抗增殖作用和激酶抑制,提供了有前途的治疗候选者.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 双重向EGFR和HER2是癌症治疗的一个关键策略.
- 含氨酸的氨酸是一种新型的潜在抗癌药物.
- 了解激酶抑制机制对于开发向疗法至关重要.
研究的目的:
- 设计,合成和评估新型含 purin 的水 (6-24a,b) 作为抗癌剂.
- 研究这些化合物与EGFR和HER2激酶域的in silico结合亲和力.
- 评估合成化合物的体外抗增殖和激酶抑制活性.
主要方法:
- 在基分子对接用于结合亲和度评估.
- 含有纯素的化衍生物的化学合成.
- 在体外抗增殖试验 (MTT) 对抗A549,SKOV-3,A2780和SKBR-3癌细胞系.
- 在体外激酶抑制试验对EGFR和HER2的测定.
- 细胞循环分析和通过流细胞计检测的细胞亡检测.
主要成果:
- 化合物19a,16b和22b表现出显著的抗扩散活性.
- 与拉帕提尼布相比,化合物19a对A549和SKBR-3细胞的疗效更高.
- 化合物19a,16b和22b显示出强大的EGFR抑制,而22b显示出对lapatinib具有同等强大的HER2抑制.
- 在19a和22b治疗时观察到G1阶段的细胞周期停止和亡诱导.
结论:
- 化合物19a,16b和22b是开发新型抗癌药物的有希望的候选物.
- 这些化合物有效地向EGFR和HER2激酶.
- 对这些化衍生物的进一步研究可能会导致新的向癌症疗法.
关键词:
欧洲农业基金会 (EGFR) 是一个.在EGFR和HER2驱动的癌症中.在HER2中,HER2是HER2.癌症 癌症 癌症 癌症 癌症埃尔洛丁尼布 (erlotinib) 是一种药物.拉帕提尼布 (lapatinib) 是一种治疗方法.含有 purin/hydrazone 的化合物.更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
相关概念视频
Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
